The Ministry of Health, Labor and Welfare (MHLW) on July 3 approved a batch of new drugs including Biogen Japan’s spinal muscular atrophy (SMA) treatment Spinraza (nusinersen), Japan’s first antisense oligonucleotide. Spinraza, which was designed as an orphan drug, earned…
To read the full story
Related Article
- Canalia, Japan’s 1st DPP-4/SGLT-2 Combo, Now Available
September 8, 2017
- Spinraza’s 9.32 Million Yen Price Tag OK’ed for Listing on Aug. 30
August 23, 2017
REGULATORY
- Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
- Japan Panel Sees No Scientific Objection to Capvaxive NIP Addition
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





